Chewable tablets have also found application in veterinary medicines. This paper reviews considerations for the formulation of chewable tablets including sensory characteristics, chewability ...

Actinogen Medical Limited (ASX: ACW) announces that a recent trial designed to confirm therapeutic blood levels of the ...

This article describes the formulation of a tablet for a specific purpose, primarily using fractional or full factorial designs. The formulation work generated a matrix that was processed by two ...

The new tablet formulation maintains BRUKINSA’s dosing flexibility by providing patients and prescribers with the option of once- or twice-daily dosing and is designed to simplify management of ...

The European Commission has approved a new film-coated tablet formulation of Sino-American oncology-focused biotech BeOne Medicines’ Brukinsa (zanubrutinib) for all approved indications.

Abbott Laboratories, the manufacturers of ritonavir-boosted lopinavir (Kaletra) announced the development of a new tablet formulation of the protease inhibitor on July 27th at the Third International ...

Tablets are often the first choice of solid dosage forms for many pharmaceutical companies. On November 16, 2021, the US-based contract service provider, CD Formulation announces that it has started ...

Below are some of the testing services newly introduced by CD Formulation: Tablet Fragility Test The tablet fragility test is purposed to determine the resistance of tablets against mechanical stress, ...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved a new film-coated tablet formulation of BRUKINSA® ...

SAN CARLOS, Calif., June 11, 2025--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has ...

BeOne Medicines Ltd., a global oncology company, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending ...

Tablets will advance treatment simplicity and convenience to meet patient needs across Europe BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced ...